Lyell Immunopharma, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
LYEL$16.75+8.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $3 | $15 | $9 | $30 |
| Operating expenses: | ||||
| Research and development | 40,898 | 28,172 | 117,026 | 106,476 |
| General and administrative | 9,297 | 10,687 | 28,428 | 34,519 |
| Other operating income, net | (1,897) | (1,591) | (5,552) | (648) |
| Impairment of long-lived assets | — | — | — | 1,443 |
| Total operating expenses | 48,298 | 37,268 | 139,902 | 141,790 |
| Loss from operations | (48,295) | (37,253) | (139,893) | (141,760) |
| Interest income, net | 1,905 | 3,266 | 6,283 | 10,404 |
| Other income (expense), net | 861 | (4,859) | 19,173 | (2,369) |
| Total other income (loss), net | 2,766 | (1,593) | 25,456 | 8,035 |
| Net loss | (45,529) | (38,846) | (114,437) | (133,725) |
| Other comprehensive loss: | ||||
| Net unrealized (loss) gain on marketable securities | (120) | 144 | (520) | (90) |
| Comprehensive loss | $(45,649) | $(38,702) | $(114,957) | $(133,815) |
| Net loss per common share, basic and diluted | $(1.86) | $(2.13) | $(4.93) | $(8.38) |
| Weighted-average shares used to compute net loss per common share, basic and diluted | 24,436 | 18,268 | 23,235 | 15,952 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.